Although airborne chemicals can cause a number of harmful effects, the most common effect is sensory irritation ([@b36-ehp0115-001609]). Exposure to a sensory irritant may stimulate the trigeminal nerve endings and laryngeal receptors, eliciting any one or a combination of the following symptoms: burning sensation of the eyes, nose, or throat, as well as coughing sensations ([@b12-ehp0115-001609]). Sensory irritation is also the most common end point for occupational exposure levels (OELs). For one specific OEL measure, threshold limit values (TLVs) \[developed by the American Conference of Governmental Industrial Hygienists ([@b1-ehp0115-001609])\] are calculated based on sensory or pulmonary irritation for \> 50% of the compounds. [@b51-ehp0115-001609] reported that approximately two-thirds of the compounds for which they found a TLV acted as sensory irritants. A qualitative evaluation of sensory irritants indicated that sensory irritation responses in the mouse are predictive of responses in humans ([@b4-ehp0115-001609]).

In 1966, Alarie initially proposed the use of an animal test to evaluate the potency of airborne sensory irritants. The bioassay uses male Swiss-Webster mice to measure decreases in respiratory frequency resulting from exposure to a geometric series of concentrations of airborne irritants ([@b3-ehp0115-001609]). The concentration inducing a 50% decrease in respiratory frequency is termed the RD~50~. From these measured RD~50~s, [@b7-ehp0115-001609] ranked irritant potencies and found a good correlation (*R*^2^) between RD~50~s and TLVs. The Alarie test evolved over the years and was adopted in 1984 as a standard test by the American Society for Testing and Materials ([@b18-ehp0115-001609]). The "RD~50~ test" or the "Standard Test Method for Estimating Sensory Irritancy of Airborne Chemicals" ([@b18-ehp0115-001609]) quantitatively measures irritancy as indicated by the reflex inhibition of respiration in mice exposed to sensory irritants. For the test, four mice are first acclimatized to the chamber and are then simultaneously exposed to the airborne chemical. A sufficient number of groups are exposed to a geometric series of concentrations so that a concentration--response curve can be constructed from the analysis. The mice are placed in a body plethysmograph attached to an exposure chamber so that only the head is exposed to the test material. The plethysmographs are connected to pressure transducers, which sense changes created by inspiration and expiration. The amplified signals are transmitted to a polygraph recorder. The concentration of airborne irritant that produces an RD~50~ is determined from the concentration--response curve constructed from the various data points obtained with a series of concentrations.

Sensory irritation is a reflex reaction from stimulation of the trigeminal or laryngeal nerve endings (Boylstein et al. 1996). The sensory irritant response is mediated through binding to the trigeminal nerve receptors and appears to follow Michaelis-Menten receptor kinetics. Although the RD~50~ concentration has been described as "intolerable" to humans, as indicated in the ASTM standard, "the test method will detect irritation effects at concentrations far below those at which pathological changes are observed" ([@b10-ehp0115-001609]; [@b18-ehp0115-001609]). Further, as demonstrated by [@b22-ehp0115-001609], pathologically detectable responses are expected only after prolonged repeated exposure.

RD~50~s are a basis, at least partially, for a number of OELs by ACGIH ([@b1-ehp0115-001609]). The calculation methodology is based on [@b51-ehp0115-001609], who evaluated data from 11 sensory irritants and concluded that a level one-hundredth of the RD~50~ would produce "minimal or no sensory irritation" in humans. The current suggestion of setting OELs at 0.03 RD~50~ comes from [@b6-ehp0115-001609], [@b7-ehp0115-001609], because 0.03 RD~50~ is halfway between 0.1 RD~50~ and 0.01 RD~50~ on a logarithmic scale. [@b6-ehp0115-001609] reported a strong correlation (*R*^2^ = 0.89) between 0.03 RD~50~ and OELs for the 26 chemicals tested. Subsequently, both analyses, one using 41 chemicals ([@b11-ehp0115-001609]) and most recently another using 89 chemicals ([@b78-ehp0115-001609]), resulted in a lower but still strong correlation (*R*^2^ = 0.78). Although most of the applications of the RD~50~ have focused on OELs, [@b65-ehp0115-001609] found that protection against indoor sensory irritation effects could be achieved at a level of 0.025--0.25 of the OEL. Multiple studies show strong correlations between RD~50~s and OELs, supporting the continued use of the Alarie test for establishing OELs ([@b51-ehp0115-001609], [@b52-ehp0115-001609]; [@b78-ehp0115-001609]).

In this study we examined the relationship between RD~50~s and human sensory irritation responses in a quantitative manner, particularly for chemicals that produce burning sensation of the eyes, nose, or throat, based on lowest observed adverse effect levels (LOAELs) reported for human subjects. We also analyzed the relationship between RD~50~s and OELs for identified human sensory irritants. Finally, we evaluated the relationship between RD~50~s and acute reference exposure levels (RELs) developed to protect the public ([@b32-ehp0115-001609]). RELs are defined as "\[t\]he concentration level at or below which no adverse health effects are anticipated for a specified exposure duration \[1 hr for the acute RELs\]. ... RELs are based on the most sensitive, relevant, adverse health effect reported in the medical and toxicological literature." A strong correlation between RD~50~s and LOAELs, TLVs, and acute RELs will support the use of RD~50~s in establishing guidance levels to protect the public from sensory irritants.

Methods
=======

LOAELs versus RD~50~s
---------------------

Using published toxicologic studies of human subjects exposed to sensory irritants, we identified human LOAELs. Criteria for selecting human LOAELs required that the studies describe mild irritating effects ([@b13-ehp0115-001609]) resulting from acute inhalation exposure. Published human studies on hazardous air pollutants (HAPs) served as the primary sources of information for these chemicals ([@b13-ehp0115-001609]). We searched PubMed (National Library of Medicine; <http://www.ncbi.nlm.nih.gov/sites/entrez>), Biosis ([www.biosis.org/](www.biosis.org/)), Current Contents (<http://scientific.thomson.com/products/ccc/>), Toxline (National Library of Medicine; <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?TOXLINE>), SciFinder Scholar (Chemical Abstracts Service; <http://www.cas.org/support/scifi/sfsolutions/index.html>), Oldmedline (<http://www.nlm.nih.gov/databases/databases_oldmedline.html>), Web of Science (<http://scientific.thomson.com/products/wos>), and Environmental Sciences and Pollution Management Databases (Cambridge Scientific Abstracts; <http://www.csa.com/factsheets/envclust-set-c.php>) to identify toxicologic studies published between 1970 and 2005 for all 189 HAPs. Search terms included the chemical name, the type of LOAEL effects (e.g., irritation), route of exposure (inhalation), and exposure duration (acute). We also conducted online searches for additional non-HAP chemicals with an identified RD~50~. Further, we conducted manual searches from secondary sources through 2005. Five criteria were developed for inclusion of a study in the analysis: *a*) peer-reviewed and published, well-conducted industry-sponsored studies or doctoral dissertations; *b*) inhalation exposure; *c*) discrete acute exposure; *d*) available LOAEL for a mild adverse health effect; and *e*) the original research. For each human study analyzed, information about the chemical, exposure time, end-point category (eye and/or respiratory irritation), and LOAELs were recorded. If multiple mild responses were reported at various dose levels for the same chemical and exposure time, then the lowest adverse effect level was considered the LOAEL.

For RD~50~s, we first reviewed references identified from the database developed by [@b78-ehp0115-001609]. We identified additional studies from [@b12-ehp0115-001609]. We also searched the scientific literature during the period 1992--2005 to identify newer published studies containing RD~50~s. For each identified study, we recorded information on the chemical, exposure time, species, and RD~50~. We reviewed the methodology used to attain each RD~50~ for consistency with current ASTM methods ([@b18-ehp0115-001609]); for this reason, we included studies with mice, but excluded studies with rats in this analysis.

In cases where both RD~50~s and human LOAELs were available for the same chemical, we log transformed and fit the data with a linear relationship using Microsoft Office Excel 2003 (Microsoft, Redmond, WA) and SAS version 9.1 (SAS Institute Inc., Cary, NC) for Windows. This procedure was similar to previous RD~50~ comparisons (e.g., [@b7-ehp0115-001609]). When we found multiple LOAELs or RD~50~s for a single chemical, we considered each reported value in the analysis. Sensitivity analyses were conducted by evaluating the correlation generated from the regression of LOAELs with RD~50~ value data sets, which varied by exposure time, or strain tested. We also conducted subanalyses using upper and lower respiratory tract effects.

RELs versus RD~50~s
-------------------

As reported by [@b32-ehp0115-001609], the California Environmental Protection Agency (EPA) has developed 51 acute inhalation RELs. We evaluateds these RELs to identify those based on eye or respiratory irritation end points in humans, and compared with RD~50~s. Using Microsoft Office Excel 2003 (Microsoft) and SAS version 9.1 (SAS) for Windows, we log transformed and fit the data with a linear relationship.

TLVs versus RD~50~s
-------------------

For all RD~50~s used in the above analyses, we identified TLVs from [@b1-ehp0115-001609]. The TLVs included time-weighted averages, short-term exposure limits and ceilings. If the documentation reported more than one TLV value, we used the lowest, more protective value. A third comparison between RD~50~s and TLVs of identified human irritants, based on identification of a human LOAEL for irritation, was conducted using log-transformed data, fit with a linear relationship, and analyzed with Microsoft Office Excel 2003 (Microsoft) and SAS version 9.1 (SAS) for Windows.

Results
=======

LOAELs versus RD~50~s
---------------------

From our search, we identified 25 chemicals with 72 human acute irritation LOAELs from 49 studies ([Table 1](#t1-ehp0115-001609){ref-type="table"}). The adverse effects, exposure times, and information reflecting the quality of the study (e.g., placebo-control, blinding, subject selection, subject characteristics, exposure design, and data reporting) are indicated in [Table 1](#t1-ehp0115-001609){ref-type="table"}. For the 25 chemicals identified, 63 RD~50~s were found in mice ([Table 2](#t2-ehp0115-001609){ref-type="table"}). The RD~50~s were based on seven mouse strains and exposure times ranging from 5 to 180 min.

[Figure 1](#f1-ehp0115-001609){ref-type="fig"} shows the correlation between RD~50~s and LOAELs for all RD~50~s identified in all strains of mice for the 25 chemicals, allowing for 198 comparisons. There is a strong overall correlation (*R*^2^ = 0.80) between RD~50~s and human irritation LOAELs. When we conducted the analysis for Swiss-Webster mice only ([Table 3](#t3-ehp0115-001609){ref-type="table"}), we were able to include 75 data points for 19 compounds, and the correlation decreased slightly (*R*^2^ = 0.74). When we evaluated only the data for non--Swiss-Webster mice ([Table 3](#t3-ehp0115-001609){ref-type="table"}), there was little change in the correlation (*R*^2^ = 0.83). We conducted several sub-analyses to consider the influence of the RD~50~ study exposure duration. As indicated in [Table 3](#t3-ehp0115-001609){ref-type="table"} there was little influence on the *R*^2^. Thus, according to this analysis, the strain of mouse tested does not appear to affect this evaluation substantially. The equations do not change significantly, and the correlation is still significant for all analyses, validating the inclusion criteria used. As indicated in [Table 3](#t3-ehp0115-001609){ref-type="table"}, we also considered several subanalyses to address the influence of the human LOAEL variability. Specifically, we considered the issue of LOAEL sensitivity, the type of irritation end point, study quality, and the duration of exposure for the human LOAEL. The only significant effect on the correlation was observed when considering human irritation end points of the lower respiratory tract; the poor *R*^2^ appears to be attributed partly to the few number of data points (29) in the analysis.

RELs versus RD~50~s
-------------------

From the 51 California acute RELs, we identified 16 that had irritation as their end point and a corresponding RD~50~. [Figure 2](#f2-ehp0115-001609){ref-type="fig"} indicates a good correlation (*R*^2^ = 0.71) between RD~50~s and RELs for 16 chemicals with 37 comparisons.

TLVs versus RD~50~s
-------------------

For the compounds identified with RD~50~s and LOAELs, 24 had a corresponding TLV. [Figure 3](#f3-ehp0115-001609){ref-type="fig"} shows the correlation of TLVs to RD~50~s with an *R*^2^ value of 0.81. Thus, when focusing specifically on human irritants, the relationship between the TLV and RD~50~ remains strong.

Conclusions
===========

The focus of this paper is on the applicability of RD~50~s for human health risk assessment. Exposure guidelines to protect workers and the public often focus on mild irritating signs or symptoms. For example, \> 50% of the TLVs and \> 60% of the California acute RELs based their end points on irritation ([@b32-ehp0115-001609]). However, human studies from which to develop acute exposure guidance are not available for many of the hundreds of substances of concern, and therefore reliance on animal studies is necessary. The RD~50~ test method is appealing because it generates data rapidly, requires minimal animal use, is low in cost, and is validated, calibrated, and standardized. The method was computerized, adding to the reproducibility of the results ([@b9-ehp0115-001609], [@b10-ehp0115-001609]; [@b92-ehp0115-001609]). The availability of RD~50~s in male mice for 89 chemicals ([@b78-ehp0115-001609]), and their correlation with OELs suggests potential applicability to air exposure guidelines for the public. The result of this analysis quantitatively supports the applicability of RD~50~s in setting exposure guidelines for the public and workers.

We found a strong correlation between RD~50~s and human LOAELs, TLVs, and California RELs. Focusing on human studies where the subjects developed eye or respiratory irritation responses, we observed a strong correlation (*R*^2^ = 0.80) between RD~50~s and LOAELs for 25 chemicals with irritating effects. The correlation remained close to 0.8 after conducting various subanalyses, indicating that the strains of mice or the RD~50~ exposure time does not substantially affect the correlation. Previously, [@b65-ehp0115-001609] proposed an indoor air guideline for the public between 0.025 and 0.25 times the OEL, similar to 0.0008 and 0.008 times the RD~50~. In our analysis, the RD~50~ to REL correlation can be expressed as REL = 0.00026 × RD~50~^1.4^. Derived as follows:
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Exposure times in the human studies varied from 1 to 480 min, and a subanalysis looking specifically at the effect of the duration of exposure made no significant change to the correlation. Further, subanalyses using LOAELs more closely associated with either upper respiratory or lower respiratory effects did not make a significant change to the correlations. Although the variability in the response rate, interindividual sensitivity, and differences in human study design, as described in [Table 1](#t1-ehp0115-001609){ref-type="table"}, would be expected to have reduced the correlation with the RD~50~, specific factors were not identified in our subanalyses. Thus, we conclude that the irritating symptoms in humans correlate well with the RD~50~s of animals irrespective of the specific acute exposure duration. These results not only support the use of the RD~50~ in setting guidelines for acutely irritating compounds, but also suggest that a concentration--time extrapolation for these effects appears unwarranted. This is consistent with the finding by [@b80-ehp0115-001609] that the human response to sensory irritants reached a plateau rapidly. Thus, the response appears to be influenced to a greater extent by the exposure concentration rather than the exposure time over the period of observation for most animal and human experiments considered in the present analysis, and over the periods of concern for the TLVs (15 min to 8 hr) and acute RELs (1 hr).

The results of this analysis are subject to several limitations. First, the number of available human studies limits the LOAEL data, and it is unlikely that human data will significantly increase in the future. The number of comparisons could increase as the numbers of RD~50~s increase for chemicals with human data. However, considering the robustness of the subanalyses, and the historical correlation of the RD~50~ to the TLV, a significant change in the RD~50~ to LOAEL correlation is unlikely after adding other sensory irritants in the analysis. Finally, we address issues raised by [@b28-ehp0115-001609], [@b26-ehp0115-001609], [@b27-ehp0115-001609]).

First, [@b27-ehp0115-001609] claimed that the RD~50~--OEL correlation is expected because most OELs are based on animal data. Although many OELs are based on animal data, many are based on human data as well. Of the 24 substances we evaluated in our RD~50~--OEL correlation, the OEL for only one compound, *n*-pentyl acetate, relied on the RD~50~ for its derivation, which was based solely on animal data. The strong correlation between RD~50~s and human LOAELs also addresses this concern.

Second, [@b26-ehp0115-001609] reported the RD~50~s did not correlate well with histopathologic changes in the respiratory tract or with corrosivity, and therefore RD~50~s were inappropriate to evaluate respiratory tract irritation. However, the stated purpose of the ASTM standard is to evaluate sensory irritation potential, not histopathology or corrosivity. In our comparison of the RD~50~s with human irritation LOAELs, the correlation was strong with the inclusion of respiratory tract irritation end points in the analysis. Further, the risk assessment framework for occupational and public exposure levels addresses the concerns regarding the potential for other, more severe effects. In cases where other health effects occur at or below levels producing sensory irritation, exposure guidelines use the more sensitive adverse effect.

Third, [@b28-ehp0115-001609] raised concerns regarding the inconsistency of RD~50~s among strains and species. Although RD~50~s have been generated for various strains and species with varying test procedures, adhering to the ASTM standard method addresses this concern. Limiting the RD~50~ test to those conducted in mice, or Swiss-Webster mice, and limiting the exposure time keeps the test to a more standardized method, although intrastrain variability was not a cause for concern in our subanalyses. Finally, we addressed the concern regarding time--concentration response curves ([@b28-ehp0115-001609]), with separate subanalyses based on exposure time. These analyses show that time did not appear to be a factor in our analyses. Our presumption is that if the study adheres adequately to the ASTM standard method, experimental exposure time plays a minor role. It is also worth pointing out that all of the figures comparing RD~50~s to LOAELs, RELs, and TLVs are plotted on a log--log plot because of the wide range of values. Because of the nature of log--log plots, the correlation is higher compared with the same correlation using a nonlogarithmic scale.

The applicability of the RD~50~ test to human health protection has been demonstrated in several analyses, but extrapolation of the test results to the general public would be improved with greater focus on the tail of the dose--response curve, to ensure protection of sensitive subpopulations. One solution would be for RD~50~ studies to report sufficient information to calculate a benchmark dose (BMD) value, and not focus solely on the specific RD~50~ value. A standardized BMD value could be calculated at the tail of the distribution, taking into account the slope of the dose--response curve. Alternatively, the test procedure could be refined to identify the "just detectable effect level," which is approximately a 12% decrease in the respiratory rate ([@b9-ehp0115-001609]). Although some work has been done in this area (Boylstein et al. 1996), additional information is needed to better understand the tail of the dose--response curve and to address any concerns for spurious results from low exposure concentrations. The reported just detectable effect level of 12% appears to be close to the no observed effect level of the procedure. Use of this response rate in risk assessment is consistent with the recommendation by the [@b90-ehp0115-001609] that the BMD for a continuous response may be set on statistical criteria of distinguishability from the control value, as well as on grounds of anticipated biological significance. A major benefit of focusing on the just detectable effect level would be to reduce potential animal suffering, and possibly animal usage.

In conclusion, the RD~50~ test is a good starting point for setting exposure standards for acute airborne irritants. As noted by [@b12-ehp0115-001609], the TLV may need to be \< 0.03 RD~50~ to prevent other toxic effects. Consequently, the literature should be adequately evaluated to determine that sensory irritation is likely the most sensitive adverse effect. The application of RD~50~s appears most useful when qualitative data are available indicating sensory irritation as the most sensitive adverse effect, but quantitative human data are lacking. The RD~50~ has proven its usefulness with the ability to appropriately rank the potency of airborne chemicals as sensory irritants and help establish exposure limits. A strong correlation between RD~50~s and LOAELs provides further support for using RD~50~s in determining guidance levels to protect the general public from sensory irritants.
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![Linear least-squares regression analysis for log RD~50~ (for all mouse strains) vs. log LOAEL (human irritation end points) for 25 compounds, using 195 data points. Log RD~50~ = 1.16(log LOAEL) + 0.77; *R* ^2^ = 0.80.](ehp0115-001609f1){#f1-ehp0115-001609}

![Linear least-squares regression analysis for log RD~50~ (mice) vs. log REL (set by OEHHA for airborne toxicants) for 16 compounds. Log RD~50~ = 0.71(log REL) + 2.55; *R* ^2^ = 0.71.](ehp0115-001609f2){#f2-ehp0115-001609}
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###### 

LOAELs for human sensory irritation for each study found in the literature.

  Compound                   LOAEL (ppm)   Time (min)   No. of subjects   \% Response[a](#tfn2-ehp0115-001609){ref-type="table-fn"}   End point[b](#tfn3-ehp0115-001609){ref-type="table-fn"}   Reference
  -------------------------- ------------- ------------ ----------------- ----------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------
  Acetaldehyde               7             5            27                0                                                           Eye irritation                                            [@b84-ehp0115-001609]
                             12            4            9                 Average[c](#tfn4-ehp0115-001609){ref-type="table-fn"}       Bronchial hyperresponsiveness (L)                         [@b62-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             50            15           12                Majority                                                    Eye irritation                                            [@b81-ehp0115-001609]
  Acetone                    300           3--5         10                Majority                                                    Eye irritation                                            [@b63-ehp0115-001609]
                             800           20           27                Average                                                     Eye and weak nasal irritation                             [@b34-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             990           240          16                100                                                         Eye, mouth, and throat irritation                         [@b79-ehp0115-001609]
                             1,000         450          4                 75                                                          Eye and throat irritation                                 Stewart et al.1975
  Acrolein                   0.44          NG           10                NG                                                          Conjuctival and nasal irritation                          [@b70-ehp0115-001609]
                             0.5           5            36                20                                                          Eye irritation                                            [@b84-ehp0115-001609]
                             0.6           5            16                Average                                                     Eye and nasal irritation                                  [@b46-ehp0115-001609]
  Allyl alcohol              0.78          5            6                 Average                                                     Slight nasal irritation                                   [@b38-ehp0115-001609]
  Ammonia                    5             180          12                100                                                         Eye irritation                                            [@b88-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             30            10           5                 40                                                          Eye and nasal irritation                                  [@b57-ehp0115-001609]
                             50            30           16                44                                                          Eye and throat irritation                                 [@b91-ehp0115-001609]
  *n*-Butyl acetate          200           3--5         10                Majority                                                    Throat irritation                                         [@b63-ehp0115-001609]
  *n*-Butanol                25            3--5         10                Majority                                                    Eye, nasal, and throat irritation                         [@b63-ehp0115-001609]
  Chlorine                   0.95          240          8                 Average                                                     Forced vital capacity decrease (L)                        [@b72-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             1             60           5                 Average                                                     FEV~1~ decrease (L)                                       [@b33-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             1             480          29                100                                                         FEV~1~ decrease (L)                                       [@b16-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             1             120          29                100                                                         Urge to cough                                             [@b16-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             1             60           29                100                                                         Throat irritation                                         [@b16-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             2             60           8                 100                                                         Urge to cough                                             [@b16-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             2             240          8                 100                                                         Forced vital capacity decrease (L)                        [@b16-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             2             120          8                 75                                                          Throat irritation                                         [@b49-ehp0115-001609]
                             2             60           8                 25                                                          Nasal irritation                                          [@b49-ehp0115-001609]
                             2             30           8                 38                                                          Nasal and throat irritation                               [@b49-ehp0115-001609]
  Ethylacetate               400           3--5         10                Majority                                                    Nasal and throat irritation                               [@b63-ehp0115-001609]
                             402           240          16                Average                                                     Eye, nasal, and throat irritation                         [@b79-ehp0115-001609]
  Formaldehyde               0.4           120          20                Average                                                     Rhinitis                                                  [@b69-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             0.5           120          20                100                                                         Nasal irritation                                          [@b54-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             0.69          480          109               Average                                                     Eye irritation                                            [@b47-ehp0115-001609]
                             1             120          16                44                                                          Conjunctival irritation                                   Anderson and Molhave 1983
                             1             6            27                100                                                         Eye irritation                                            [@b25-ehp0115-001609]
                             1             5            75                8                                                           Eye irritation                                            [@b84-ehp0115-001609]
                             1             1.5          48                Average                                                     Nasal irritation                                          [@b94-ehp0115-001609]
                             1             90           18                84                                                          Eye, nasal, and throat irritation                         [@b35-ehp0115-001609]
                             1.01          180          19                21                                                          Eye irritation                                            [@b56-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             2             10           15                53                                                          Eye irritation                                            [@b77-ehp0115-001609]
                             2             40           15                60                                                          Eye irritation                                            [@b76-ehp0115-001609]
                             3             180          9                 Average                                                     Eye, nasal, and throat irritation                         [@b74-ehp0115-001609]
                             3             180          9                 Average                                                     Eye, nasal, and throat irritation; FEV~1~ decrease (L)    [@b75-ehp0115-001609]
                             3.01          20           24                Average                                                     Eye, nasal, and throat irritation                         [@b43-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
  Isophorone                 25            15           12                NG                                                          Eye, nasal, and throat irritation                         [@b81-ehp0115-001609]
  Isopropyl acetate          200           15           12                Majority                                                    Eye irritation                                            [@b81-ehp0115-001609]
  Isopropanol                400           3--5         10                Majority                                                    Eye, nasal, and throat irritation                         [@b63-ehp0115-001609]
  Methanol                   1025          240          1                 100                                                         Eye irritation                                            [@b17-ehp0115-001609]
  Methyl ethyl ketone        100           3--5         10                Majority                                                    Nasal and throat irritation                               [@b63-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             200           240          19                Average                                                     Subclinical rhinitis                                      [@b61-ehp0115-001609]
  Methyl isocyanate          0.5           10           6                 100                                                         Eye, nasal, and throat irritation                         [@b82-ehp0115-001609]
                             1.75          1            8                 38                                                          Nasal irritation                                          [@b82-ehp0115-001609]
                             2             1            4                 100                                                         Eye irritation                                            [@b53-ehp0115-001609]
                             2.5           120          7                 57                                                          Nasal irritation                                          [@b71-ehp0115-001609]
  Nitrogen dioxide           1.5           180          15                Average                                                     Increased airway reactivity (L)                           [@b40-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             2             60           18                Average                                                     Increased airway reactivity (L)                           [@b58-ehp0115-001609][d](#tfn5-ehp0115-001609){ref-type="table-fn"}
                             2.5           120          16                Average                                                     Increased airway resistance (L)                           [@b24-ehp0115-001609]
                             5             120          16                Average                                                     Increased airway resistance (L)                           [@b93-ehp0115-001609]
  *n*-Pentanol               100           3--5         10                Majority                                                    Throat irritation                                         [@b63-ehp0115-001609]
  *n*-Pentyl acetate         100           3--5         10                Majority                                                    Throat irritation                                         [@b63-ehp0115-001609]
  Styrene                    14.7          15           2                 100                                                         Bronchospasm (L)                                          [@b59-ehp0115-001609]
                             216           20           3                 3                                                           Nasal irritation                                          [@b85-ehp0115-001609]
                             600           1            NG                NG                                                          Eye and nasal irritation                                  [@b95-ehp0115-001609]
                             800           240          2                 100                                                         Eye and throat irritation                                 [@b30-ehp0115-001609]
  Sulfur dioxide             5             300          14                Average                                                     Increase in discomfort, irritation                        [@b15-ehp0115-001609]
  Toluene                    100           360          16                Average                                                     Eye irritation                                            Anderson and Molhave 1983
                             100           390          24                Average                                                     Nasal and lower airway irritation                         [@b19-ehp0115-001609]
                             200           210          2                 100                                                         Eye and throat irritation                                 [@b30-ehp0115-001609]
                             300           3--5         10                Majority                                                    Eye and throat irritation                                 [@b63-ehp0115-001609]
  Toluene-2,4-diisocyanate   0.01          900          15                7                                                           Increased airway resistance (L)                           [@b23-ehp0115-001609]
  Triethylamine              4.35          480          2                 100                                                         Visual disturbances, discomfort                           [@b2-ehp0115-001609]
                             8.22          240          2                 100                                                         Visual disturbances, discomfort                           [@b2-ehp0115-001609]
                             11.6          60           2                 100                                                         Visual disturbances, discomfort                           [@b2-ehp0115-001609]
  *p*-Xylene                 100           450          11                18                                                          Eye and respiratory irritation                            [@b44-ehp0115-001609]

Abbreviations: FEV~1~, forced expiratory volume in 1 sec; NG, not given. For some studies, multiple experiments were conducted with different exposure times or end points resulting in multiple LOAELs for the compounds.

Numerical values indicate the percent of subjects responding.

End points with (L) depict "Lower" respiratory end points; all others are "Upper" respiratory end points.

"Average" indicates that the response was a mean response.

Study was considered to be of higher quality due to study design (e.g., placebo-controlled, blinding, subject selection, subject characteristics, exposure conditions, and/or data reporting).

###### 

RD~50~s of male mice with their corresponding TLVs[a](#tfn7-ehp0115-001609){ref-type="table-fn"} and RELs[b](#tfn8-ehp0115-001609){ref-type="table-fn"} (ppm), along with the specific strain of mice used in the experiment and reference.

  Compound              RD~50~ (ppm)   Exposure time (min)   TLV (ppm)   REL (ppm)   RD~50~ strain   RD~50~ reference
  --------------------- -------------- --------------------- ----------- ----------- --------------- --------------------------------------------------------------------
  Acetaldehyde          2,845          10                    25          NA          SW              [@b83-ehp0115-001609]
                        2,932          10                    25          NA          B6C3F~1~        [@b83-ehp0115-001609]
                        4,946          10                    25          NA          SW              [@b52-ehp0115-001609]
  Acetone               23,480         5                     500         NA          OF1             [@b36-ehp0115-001609]
                        77,156         10                    500         NA          SW              [@b52-ehp0115-001609]
  Acrolein              1.03           10                    0.1         0.00009     SW              [@b83-ehp0115-001609]
                        1.41           10                    0.1         0.00009     B6C3F~1~        [@b83-ehp0115-001609]
                        1.66           10                    0.1         0.00009     BALB/c          [@b60-ehp0115-001609]
                        1.7            1                     0.1         0.00009     SW              [@b50-ehp0115-001609]
                        2.9            30                    0.1         0.00009     CF1             [@b66-ehp0115-001609]
  Allyl alcohol         1.6            5                     0.5         NA          OF1             [@b60-ehp0115-001609]
                        2.5            30                    0.5         NA          ICR             [@b48-ehp0115-001609]
                        3.9            30                    0.5         NA          CF1             [@b66-ehp0115-001609]
  Ammonia               303            30                    25          4.5         SW              [@b20-ehp0115-001609]
                        789.6          10                    25          4.5         CF1             [@b89-ehp0115-001609]
  *n*-Butyl acetate     730            5                     150         NA          OF1             [@b60-ehp0115-001609]
  *n*-Butanol           1,268          5                     20          NA          OF1             [@b36-ehp0115-001609]
                        4,784          10                    20          NA          SW              [@b52-ehp0115-001609]
                        11,696         30                    20          NA          CF1             [@b55-ehp0115-001609]
  Chlorine              3.50           120                   0.5         0.07        OF1             [@b41-ehp0115-001609]
                        9.3            10                    0.5         0.07        SW              [@b21-ehp0115-001609]
                        11.97          10                    0.5         0.07        BALB/c          [@b89-ehp0115-001609]
  Ethylacetate          580            5                     400         NA          OF1             [@b36-ehp0115-001609]
                        614            10                    400         NA          SW              [@b52-ehp0115-001609]
  Formaldehyde          3.1            10                    0.3         0.076       SW              [@b50-ehp0115-001609]
                        4              10                    0.3         0.076       BALB/c          [@b67-ehp0115-001609]
                        4.9            10                    0.3         0.076       B6C3F~1~        [@b31-ehp0115-001609]
                        5.3            5                     0.3         0.076       OF1             [@b36-ehp0115-001609]
  Isophorone            27.8           5                     5           NA          OF1             [@b36-ehp0115-001609]
  Isopropyl acetate     4,259          5                     100         NA          OF1             [@b60-ehp0115-001609]
  Isopropanol           5,000          5                     200         1.3         OF1             [@b36-ehp0115-001609]
                        17,693         10                    200         1.3         SW              [@b52-ehp0115-001609]
  Methanol              25,222         5                     200         NA          OF1             [@b60-ehp0115-001609]
                        41,514         10                    200         NA          SW              [@b52-ehp0115-001609]
  Methyl ethyl ketone   9,000          10                    200         4.5         SW              [@b87-ehp0115-001609]
                        10,745         5                     200         4.5         OF1             [@b36-ehp0115-001609]
                        31,426         30                    200         4.5         CF1             [@b45-ehp0115-001609]
  Methyl isocyanate     1.3            90                    0.02        NA          SW              [@b39-ehp0115-001609]
                        2.9            30                    0.02        NA          ICR             [@b48-ehp0115-001609]
  Nitrogen dioxide      349            10                    3           0.25        SW              [@b8-ehp0115-001609]
  Phenol                166                                  5           1.5         OF1             [@b36-ehp0115-001609]
  *n*-Pentanol          4,039          10                    NA          NA          SW              [@b52-ehp0115-001609]
                        5,933          5                     NA          NA          OF1             [@b60-ehp0115-001609]
  *n*-Pentyl acetate    1,531          10                    50          NA          SW              [@b6-ehp0115-001609]
                        1,562          5                     50          NA          OF1             [@b60-ehp0115-001609]
  Styrene               156.3          3                     20          5.1         SW              [@b5-ehp0115-001609]
                        586            5                     20          5.1         OF1             [@b36-ehp0115-001609]
                        980            10                    20          5.1         SW              [@b6-ehp0115-001609][a](#tfn7-ehp0115-001609){ref-type="table-fn"}
  Sulfur dioxide        117                                  2           0.25        SW              [@b6-ehp0115-001609][a](#tfn7-ehp0115-001609){ref-type="table-fn"}
  Toluene               3,373          5                     50          9.8         OF1             [@b36-ehp0115-001609]
                        4,900          10                    50          9.8         SW              [@b37-ehp0115-001609]
                        5,300          30                    50          9.8         SW              [@b64-ehp0115-001609]
  2,4-Toluene           0.24           40                    0.005       NA          OF1             [@b36-ehp0115-001609]
  Diisocyanate          0.39           30                    0.005       NA          SW              [@b20-ehp0115-001609]
                        0.78           180                   0.005       NA          SW              [@b73-ehp0115-001609]
  Triethylamine         156            15                    1           0.68        OF1             [@b42-ehp0115-001609]
                        186            30                    1           0.68        CF1             [@b68-ehp0115-001609]
  *p-*Xylene            1,325          5                     100         5           OF1             [@b60-ehp0115-001609]

NA, not available.

RELs as described in [@b32-ehp0115-001609].

TLVs developed by [@b1-ehp0115-001609].

###### 

Summary of linear least-squares regression analyses for various comparisons.

  Basic analyses                                                                                                                    No. of compounds included   No. of data points included   Regression line                       *R*^2^ value
  --------------------------------------------------------------------------------------------------------------------------------- --------------------------- ----------------------------- ------------------------------------- --------------
  Description of analysis                                                                                                                                                                                                           
   All RD~50~s identified in all strains of mice vs. all human LOAELs identified ([Figure 1](#f1-ehp0115-001609){ref-type="fig"})   25                          198                           logRD~50~ = 1.16(log LOAEL) + 0.77    0.82
   Evaluation using male mice and RELs set by OEHHA for airborne toxicants ([Figure 2](#f2-ehp0115-001609){ref-type="fig"})         16                          37                            logRD~50~ = 0.71(log REL) + 2.55      0.71
   Evaluation using male mice and the TLV ([Figure 3](#f3-ehp0115-001609){ref-type="fig"})                                          24                          61                            logRD~50~ = 0.86(log TLV) − 1.13      0.86
  Addressing issues of human LOAEL variabilities                                                                                                                                                                                    
   Evaluation using all RD~50~s identified in all strains of mice vs. the lowest human LOAEL for each compound                      25                          58                            logRD~50~ = 1.13(log LOAEL) + 1.26    0.81
   Analysis for male mice log RD~50~ vs. log LOAEL using lowest RD~50~ values with the lowest LOAEL values                          25                          25                            logRD~50~ = 1.01(log LOAEL) + 1.21    0.77
   Analysis for male mice log RD~50~ and human log LOAEL for lower respiratory end points                                           5                           29                            logRD~50~ = 1.06(log LOAEL) + 1.21    0.58
   Analysis for male mice log RD~50~ and human log LOAEL for upper respiratory end points                                           23                          166                           logRD~50~ = 1.22(log LOAEL) + 0.69    0.82
   Analysis for male mice log RD~50~ and human log LOAEL for higher quality human studies                                           7                           43                            logRD~50~ = 1.40(log LOAEL) + 0.98    0.82
   Analysis for male mice log RD~50~ and human log LOAEL for human studies not selected as higher quality                           25                          155                           log RD~50~ = 1.16(log LOAEL) + 0.73   0.79
  Evaluating influence of mouse strain                                                                                                                                                                                              
   Evaluation using only Swiss-Webster mice and all human LOAEL values ([Figure 2](#f2-ehp0115-001609){ref-type="fig"})             19                          75                            logRD~50~ = 1.12(log LOAEL) + 0.93    0.74
   Evaluation using all non--Swiss-Webster mice and all human LOAEL values ([Figure 3](#f3-ehp0115-001609){ref-type="fig"})         23                          120                           logRD~50~ = 1.20(log LOAEL) + 0.73    0.83
  Evaluating changes in exposure duration                                                                                                                                                                                           
   Evaluation using male mice and human LOAEL values from exposures of ≤ 10 min                                                     16                          67                            logRD~50~ = 1.27(log LOAEL) + 0.726   0.76
   Evaluation using male mice and human LOAEL values from exposures of \> 10 min                                                    18                          127                           logRD~50~ = 1.11(log LOAEL) + 0.838   0.80
   Evaluation using male mice and human LOAEL values from exposures of ≥ 60 min                                                     15                          101                           logRD~50~ = 1.08(log LOAEL) + 0.89    0.80
   Log RD~50~ vs. log RD~50~ for RD~50~ values with time \< 10 min                                                                  16                          44                            logRD~50~ = 1.04(log LOAEL) + 0.76    0.77
   Log LOAEL vs. Log RD~50~ for RD~50~ values with time \> 10 min                                                                   10                          43                            logRD~50~ = 1.51(log LOAEL) + 0.56    0.87
   Log RD~50~ vs. log LOAEL for RD~50~ values with time equivalent to 10 min                                                        16                          111                           logRD~50~ = 1.3(log LOAEL) + 0.78     0.80
   LogRD~50~ vs. log LOAEL for RD~50~ values at times not equivalent to 10 min                                                      22                          86                            logRD~50~ = 1.09(log LOAEL) + 0.77    0.8

OEHHA, Office of Environmental Health Hazard Assessment.
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